JAK2 and colorectal cancer: PRRX1 upregulation promotes proliferation, stemness, and chemoresistance in colorectal cancer cells by activating the interleukin-6 (IL-6)/JAK2/STAT3 axis, with IL-6 inhibition reversing its effects on stemness and chemoresistance.